Payam Javan: Amgen has announced the launch of a new online platform, AmgenNow, through which it will sell its cholesterol-lowering drug Repatha directly to U.S. consumers at a discounted rate. The Thousand Oaks, California-based biotechnology company said the initiative supports the Trump Administration’s efforts to reduce prescription drug costs. Through this program, patients can purchase Repatha for $239 per month, approximately 60 percent below the current list price.

The announcement follows similar moves by other pharmaceutical companies, including Pfizer, which recently committed to offering “most favored nation” pricing to Medicaid programs under the administration’s pricing reform initiative. The policy aims to align U.S. drug prices with the lowest rates available in other developed nations. President Trump had urged pharmaceutical companies to comply by September 30, warning of potential tariffs on imported medications for noncompliance.

According to Amgen’s Executive Vice President of Global Commercial Operations, Murdo Gordon, the AmgenNow program is designed to improve access for uninsured or out-of-pocket patients. The service is now available to all Repatha users, including those covered by Medicare, Medicaid, or other government health programs, without requiring prior authorization for prescribed patients. Repatha will also be featured on TrumpRx, a forthcoming federal direct-to-consumer prescription platform.